Navigation Links
Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies
Date:8/4/2010

CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Cytel Inc., premier provider of adaptive clinical trial design services and software, recently unveiled Compass®: the very first industrial strength software package for adaptive dose-finding studies based on frequentist or Bayesian methods.

The FDA's recently issued adaptive trial guidelines draft encourages adaptive design use, especially in attempts to identify the optimal dose level. 

Cytel has been at the forefront of applying adaptive trials in clinical practice for several years. Compass® has been developed from this experience and knowledge gained by East®, the extensively used adaptive and group sequential software for registration studies. Compass® now extends Cytel's adaptive design software line to include phase 2 dose-finding clinical trials.

Designers of dose ranging studies are challenged to find the correct dose(s) to carry into confirmatory development. The PhRMA Adaptive Dose Response Group has shown that adaptive methods often substantially improve on traditional designs at this crucial best dose determination stage.

Wider use of adaptive trials at this stage was previously inhibited by the lack of validated commercial software. Sponsor statisticians and their regulatory counterparts could only attempt to write their own statistical design code.

The advent of Compass® provides study planners with a workflow for modern dose identification study construction using accepted adaptive methods.  The built-in high-speed simulation engine quantifies design option decision-making, while visualizations of the trial characteristics improve understanding amongst both development teams and regulators, too.

A demonstration is replay-able at: http://www.cytel.com/News/Webinars.aspx

Of the release milestone, Compass® Product Manager, Yannis Jemiai, Ph.D., said: "We're very proud of our collective work to place modern, industrial strength adaptive design tools in the hands of the drug developers engaged in dose-finding clinical research. Compass® users will more easily choose the best options and conduct successful adaptive trials. Our trial simulations implementation is based on techniques proven to help sponsors to make knowledgeable decisions time and time again."  

About Cytel Inc.

47 of the top 50 biopharmaceutical firms use Cytel software to design, simulate and analyze their clinical studies. Cytel serves trial sponsors with innovative tools, training and consultation to increase clinical development efficiencies and success rates.


'/>"/>
SOURCE Cytel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
2. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
3. Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):